Abstract 4055: Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung cancer patients responding to atezolizumab treatment
Mahesh Yadav(University of Florida), Evan W. Newell(Agency for Science, Technology and Research), Hermi Sumatoh(Singapore Immunology Network), Alessandra Nardin(Singapore Immunology Network), David S. Shames(Gene Therapy Laboratory), Boon Heng Lee(Novartis (Singapore)), Bria O'Gorman, Michael Fehlings(University of Toronto), Priti S. Hegde(Foundation Medicine (United States)), Marcus Ballinger, Suchit Jhunjhunwala(Unknown), Susan Flynn(University of California System), Leesun Kim(Ulsan National Institute of Science and Technology)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k